Dicerna Pharmaceuticals
May 4, 2015

Dicerna to Present at the 17th Annual TIDES: Oligonucleotide and Peptide® Therapeutics From Research through Commercialization Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference therapeutics, today announced that Bob D. Brown, Ph.D., chief scientific officer, will present preclinical conjugate data at the 17th Annual TIDES: Oligonucleotide and Peptide Therapeutics From Research through Commercialization Conference. The presentation will take place at The Town and Country Resort on Wednesday, May 6, 2015 at 9:30 a.m. PT in San Diego, Calif.

Dicerna will present "The Translation of DsiRNA-EX Conjugate Delivery in Mouse Models to Non-Human Primate Models." The presentation will be available after the presentation event on Dicerna's website in the events & presentation section at www.dicerna.com.

About Dicerna Pharmaceuticals, Inc.

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

Investor Contact:
Westwicke Partners
Peter Vozzo, 443-213-0505
peter.vozzo@westwicke.com
or
Media Contact:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

Source: Dicerna Pharmaceuticals, Inc.

News Provided by Acquire Media